Inve India ▾

Syngene International share price & results

Syngene International Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Bengaluru CRDMO: integrated drug discovery, development & manufacturing for global pharma/biotech clients.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue736 ₹ crore−15.8% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin12.3 %−11.3 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit-9.0 ₹ crore−110.4% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity6.19 %−2.1 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin14.63 %+3.7 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)-3.41 %−1.7 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

5 of 8 judged targets kept · 10 open · verdicts reflect calls analysed to Q1 FY27.

Syngene International Limited management guidance track record on Inve: 18 targets tracked across analysed earnings calls (5 achieved, 3 missed, 10 open).

TargetOriginal wordingSaidLatest callVerdict
Bayview Facility OperationalizationH2 FY26
Call transcript, Q1 FY26 · 24 Jul 2025		Q1 FY26Q1 FY27:Operationalization confirmed for 'later this year' (FY27), but revenue contribution is now pushed out to FY28, indicating a further delay in commercial impact.
Call transcript, Q1 FY27 · 30 Jul 2026		Delayed
FY26 Reported Revenue Growthmid-single-digit range
Call transcript, Q4 FY25 · 24 Apr 2025		Q4 FY25Q4 FY26:Full-year revenue grew 3%, missing the original 'mid-single-digit' guidance but significantly beating the revised guidance of a 3-5% decline.
Call transcript, Q4 FY26 · 30 Apr 2026		Achieved*
FY26 Effective Tax Rate26%
Call transcript, Q4 FY25 · 24 Apr 2025		Q4 FY25Q4 FY26:The final effective tax rate for FY26 was not disclosed in the Q4 earnings report, leaving the final outcome of the revised 21-23% guidance unconfirmed.
Call transcript, Q4 FY26 · 30 Apr 2026		Ghosted

Source: Inve Guidance Tracker for Syngene International Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

3 of Syngene International Limited's 18 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 15 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹359.85 −1.91% · −₹7

Last close 26 Oct 2026 · NSE · INR · Source: Inve

Performance −45.5% 1Y

₹400₹500₹600Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q3 FY26 — 23 Jan 2026Q4 FY26 — 30 Apr 2026Q1 FY27 — 30 Jul 2026

1Y: ₹659.85 on 24 Oct 2025 → ₹359.85. High ₹663.85 (12 Nov 2025), low ₹346 (8 Oct 2026).

Previous close
₹366.85
Market cap
₹14.8k Cr
52-week range
₹346 – ₹663.85
One year
−45.51%
Price to earnings (TTM to Jun 2026)
49.95×
Return on equity (TTM to Jun 2026)
6.19%

Overview

Symbol
NSE:SYNGENE
Exchange
NSE
Currency
INR

What Syngene International Limited does

Based on the company's own presentations, annual report and earnings calls.

Syngene International is an integrated contract research, development and manufacturing organisation (CRDMO) providing outsourced R&D and manufacturing services to pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty-chemicals companies. It earns through fee-for-service, dedicated full-time-equivalent (FTE) team and milestone/outcome-based engagement models that span drug discovery, preclinical and clinical development, and commercial-scale manufacturing of both small and large molecules, including biologics, antibody-drug conjugates, peptides and oligonucleotides. It operates across four campuses - three in India (Bengaluru, Mangalore, Hyderabad) and one in Baltimore, USA - housing discovery laboratories, cGMP biologics and API manufacturing plants, and clinical/translational research facilities. Syngene does not sell its own branded drugs; client-funded intellectual property and molecules developed under contract remain owned by its pharma and biotech partners.

Segments

  • Research Services (CRO)
  • Dedicated R&D Centers
  • Development Services (Translational & Clinical Research)
  • Contract Development and Manufacturing Services (CDMO)
Global campuses
4 (Bengaluru, Mangalore & Hyderabad, India; Baltimore, USA)
Scientists on staff
5,778
Active clients
~400, including 16 of the top 20 global pharma companies
R&D and manufacturing infrastructure
3+ million sq. ft. across campuses
Patents held by clients from Syngene-enabled research
400+
Regulatory-approved / accredited facilities
US FDA, EMA, UK VMD, Health Canada and PMDA approved; AAALAC accredited and GLP certified
Founded 1993Headquarters Bengaluru, Karnataka, IndiaEmployees 8,373 (March 31, 2026) Company website

How the price took the results

close before → close after

Q1 FY27
−3.6%
30 Jul
Q4 FY26
+8.2%
30 Apr
Q3 FY26
−8.2%
23 Jan

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Syngene International Limited

Free account: one company. Everything above stays public.

Write why you follow Syngene International Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Syngene International Limited

Guides on how to read this kind of business and the numbers that matter.